November 30, 2018
The Japan arm of Celgene said on November 29 that it has applied for an additional indication for the treatment of oral ulcers due to Behcet’s disease for its oral phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast). The application, which was...read more